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Abstract
Background: The management of slow or non-healing ulcerations constitutes an increasing clinical challenge in the
developed world because of the ageing of the population and the pandemic rise in type II diabetes. Recent studies suggest
that molecular circuitries deployed by tumor cells to promote cancerous growth may also contribute to tissue regeneration.
Here, we exploited this emerging information to search for novel molecular targets to accelerate wound healing.
Methodology/Principal Findings: We found that the activation of the PI3K-Akt-mTOR pathway, whose aberrant function is
a frequent event in human neoplasia, represents an integral component of the normal wound healing process. By the use of
genetically defined approaches, including the epithelial-specific ablation of Pten and Tsc1, we show that mTOR activation
can dramatically increase epithelial cell proliferation, migration, and cutaneous wound healing, while pharmacological
inhibition of mTOR with rapamycin delays wound closure.
Conclusions/Significance: Overall, our findings indicate that the transient pharmacologic activation of the PI3K-Akt-mTOR
signaling axis may represent a novel clinical intervention strategy to accelerate the healing of debilitating and life-
threatening wounds.
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Introduction
Humans display a remarkable capacity to heal injured tissues
after external trauma to the body. This capacity, however, may be
compromised by the large size of the injury, by underlying medical
conditions, or by advanced age. For example, critical-size burn
victims, patients who received chemotherapy and/or radiothera-
py, elderly, and diabetic patients often present with slow or non-
healing ulcers that constitute a significant clinical challenge, and
the public health impact of non-healing wounds is likely to
increase within the coming decades, due to the ageing of the world
population and the pandemic rise in type II diabetes [1,2,3].
Certain molecular pathways that are exploited by tumor cells to
promote cancer progression have been recently shown to play also
a primary physiological role in the regeneration of injured tissues
[4,5,6]. In this regard, the phosphatidylinositol 3 kinase (PI3K)-
Akt pathway is one of the most frequently aberrantly activated
intracellular signaling routes in cancer [7,8,9,10]. The persistent
activation of growth factor receptors by mutations or autocrine
and paracrine mechanisms, gene amplification resulting in
overexpression of PI3K and/or mutations in its coding sequence
rendering this lipid kinase constitutively active, as well as
decreased activity of the lipid phosphatase PTEN by multiple
genetic or epigenetic events, all converge to promote the aberrant
accumulation phosphatidylinositol-3,4,5-triphosphate (PIP3)i n
cancer cells, thereby causing the activation of the serine-theronine
kinase Akt and its downstream targets, including the mammalian
target of rapamycin (mTOR) [7,8,11]. These observations
prompted us to explore whether the PI3K-Akt pathway partici-
pates in wound repair, as well as whether the targeted activation of
this signaling pathway represents a suitable approach to accelerate
wound healing. We show here that PI3K-Akt activation promotes
cutaneous wound repair via mTor. More importantly, we
demonstrate that elevating mTor activity dramatically accelerates
the healing process, suggesting a novel strategy for the clinical
management of slow or non-healing ulcerations.
Results
The Akt/mTOR signaling pathway is up regulated in
wound healing
To begin addressing whether the PI3K/Akt pathway is
activated during normal wound healing, we performed incisional
skin wounds in mice and harvested tissues for molecular analysis.
The stratified squamous epithelium adjacent to the wound site
(Figure 1, normal) is organized into the basal layer that
progressively differentiates into the spinous layer, granular layer
and finally the stratum corneum. These four layers express distinct
cytokeratins. For example, cytokeratin (K) 14 is expressed on the
basal layer while and K10 is expressed in the suprabasal layers.
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10643During wound healing, migrating keratinocytes form a thin
wedge-shape epithelial tongue of a few cell layers which establish
the leading wound edge (figure 1- Epithelial tongue). There is also
an increase in the thickness of the spinous layer adjacent to the
wound and a rapid proliferation of epithelial cells immediately
next to the migrating epithelial tongue (figure 1- Transitional)[1].
During the healing process, proliferation and migration are
intimately related, with hyperproliferative cells in the transitional
tissue feeding the migrating epithelial sheaths that form the
epithelial tongue, as part of an interdependent process [1,12].
We next analyzed the status of activation of the PI3K/Akt
pathway during wound healing. In normal skin, phosphorylated
forms of the S6 ribosomal protein, pS6, and serine 473 Akt,
pAkt
473, which represent downstream targets of mTOR complex 1
and mTOR complex 2 respectively [13,14], accumulate in the
granular layer, consistent with our recent findings in postnatal skin
development [15]. During wound healing, however, there is an
expansion of the cell layers exhibiting pAkt
473 and pS6 in the
spinous layer of the transitional epithelium, and a remarkable
phosphorylation of these molecules in all layers in the migrating
epithelial tongue. The most striking was the presence of pAkt
473
and pS6 in the basal layer of the epithelial tongue, which was
always absent from the normal epithelium (Figure 1).
Pten excision accelerates wound closure
To begin exploring the contribution of the PI3K/Akt/mTOR
pathway to wound healing, we first perturbed this pathway by
excising Pten, a key negative regulator of this signaling axis [11].
Figure 1. The Akt-mTOR pathway is upregulated during wound healing. (Upper panel). Representative histological sections of skin after
incisional cutaneous wounds in mice. H&E stained section displaying the histological characteristics of the unwounded epithelium (normal adjacent)
followed by an increase in the thickness of the spinous layer (acanthosis) (transitional), and the presence of migrating epithelial cells that form an
epithelial tongue (epithelial tongue) at the wound edge. (second panel from top). Immunofluorescence for Cytokeratins 10 and 14 (K10-14, red)
reveals the epidermal layer, which is delineated from the dermis by a white dotted line. Note the expansion of pAkt
473 and pS6 (red) during wound
healing from a single cell layer in the granular layer to multiple cell layers in the transitional epithelium, followed by expression in all cell layers
including the basal layer in the migrating epithelial tongue (lower two panels). Cell nuclei were stained with DAPI (blue) and fibrin(ogen) with a FITC-
conjugated antibody (green) in all panels. Scale bar, 50 mm and 100 mm, as indicated.
doi:10.1371/journal.pone.0010643.g001
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the skin by crossing mice harboring a floxed Pten allele (Pten
F/F)
with mice expressing the Cre recombinase under the control of the
K14 promoter (K14Cre). Incisional skin wounds were performed
in control and Pten epithelial-specific conditional knockout mice
(K14Cre Pten
F/F). A clearly faster rate of healing upon Pten excision
from the skin mice was apparent as early as 4 days after wounding
(Figure 2A), which was confirmed by quantification of the wound
area (p=0.0071, Figure 2B). Analysis of wound closure also
indicated that the Pten epithelial-specific conditional knockout
mice display a significant increase in the rate of wound healing,
with half of the K14Cre Pten
F/F mice healing by day 7, compared
to the control mice that displayed a median wound closure of 11
days (p,0.0001, Figure 2C).
Pten excision leads to upregulation of Akt/mTor pathway
and enhanced epithelial migration
To test whether accelerated wound healing correlated with Akt
and mTor activation, tissue samples were harvest at day 4 post
wounding. Immunohistochemical staining of wound samples
showed that the levels of pAkt
473 and pS6 were enhanced in the
suprabasal, spinous, and granular cell layers in the transitional skin
of Pten conditional knockout mice (Figure 2D-transition) as
compared to non-wounded epithelium (Figure 2D, normal). Pten
excision enhanced epidermal proliferation as reflected by the
number of BrDU-positive keratinocytes in the transitional
compartment adjacent to the wound edge (Figure 2E,
p=0.0331). In addition, the wounds of K14Cre Pten
F/F mice
were characterized by the presence of an elongated migrating
epithelial tongue that displayed high levels of expression of pAkt
473
and pS6 (Figure 2D). In line with this observation, the Pten
epithelial-specific conditional knockout mice showed accelerated
re-epithelization as judged by the direct quantification of the
length of the epithelial migrating tongue (p=0.0268, Figure 2F).
This increased migratory behavior could be recapitulated in
primary keratinocyte cultures from control and K14Cre Pten
F/F
mice (Figure 3A–3B). As expected, Pten was almost absent in
keratinocytes isolated from K14Cre Pten
F/F mice (Figure 4A, top
panel). Using a scratch wound assay, we observed that excision of
Pten accelerated keratinocyte migration into the denuded area
(p=0.0002, Figure 3A–3B). These results are aligned with in vitro
studies linking Pten with cell polarization and directional
migration [16,17]. In addition, the lack of Pten expression led to
an enhanced proliferation of the primary keratinocytes (p,0.001,
Figure 3C). The addition of EGF, a growth and pro-migratory
factor that stimulates the PI3K-Akt pathway, served as an internal
control. While EGF promoted the proliferation of control
keratinocytes to nearly the same levels than Pten deficient cells,
this growth factor failed to increase the proliferation of
keratinocytes lacking Pten, likely because they may have already
achieved a maximal proliferative capacity due to the persistent
activation of Akt in the absence of Pten. Indeed, elevated levels of
pAkt
308, pAkt
473, and pS6 were also observed in primary cultures
of keratinocytes isolated from K14Cre Pten
F/F mice (Figure 4A),
albeit primary keratinocyte cultures from control mice often have
demonstrable basal levels of pS6. Rapamycin treatment, which
inhibits mTOR [14,18], led to a complete ablation of pS6
phosphorylation, although it had only a limited impact on
pAkt
Ser473 levels (Figure 4A), aligned with a direct effect of
rapamycin on the mTORC1 complex after short time treatment
[19,20]. Rapamycin caused a decreased proliferation of control
and Pten knock out keratinocytes (Figure 4B), supporting a role for
mTOR in epithelial cell growth in wild type cells as well as
downstream from Pten.
Rapamycin delays healing in vivo
Accumulated experience in the clinic suggests that prolonged
rapamycin treatment may result in delayed wound healing
[21,22]. This was reflected in a significant delay in wound closure
upon rapamycin treatment of control mice when compared to
mice treated with vehicle (p=0.0154, Figure 4C). We also
analyzed the consequences of chronic and long term use of
rapamycin by performing incisional wounds on mice treated for
more than 6 months with rapamycin, which delayed wound
closure to an extent similar to that caused by rapamycin
administration during the acute wound healing studies (data not
shown). Using this pharmacological approach, we next investigat-
ed whether mTor contributes to the acceleration of wound healing
caused by Pten deletion. K14Cre Pten
F/F mice treated with
rapamycin presented a delayed wound closure when compared to
vehicle injected K14Cre Pten
F/F mice (p,0.0001, Figure 4D).
These results showed that inhibition of mTOR in vivo abrogates
the accelerated wound healing caused by Pten deletion in the
epithelial compartment, thus suggesting an important role for
mTor in the wound healing process downstream from PI3K and
Pten.
Activation of mTor in the epithelial compartment
accelerates wound closure
As rapamycin may exert multiple effects upon mTOR
inhibition in the epithelial and stromal compartments of the
wound area, we sought to examine the direct consequences on
wound healing of the conditional activation of mTOR in the
epithelial cells. The pathway linking PI3K-Akt to mTOR is
initiated by phosphorylation and inactivation of the tumor-
suppressor protein, tuberous sclerosis complex protein 2 (TSC2)
by Akt [23]. TSC2 associates with a second tumor-suppressor
protein, tuberous sclerosis complex protein 1 (TSC1), acting
together as a GTPase activating protein (GAP) for the small
GTPase Rheb1. The inactivation of TSC2/TSC1 complex by Akt
leads to the accumulation of the GTP-bound (active) form of
Rheb1, which in turn promotes the direct activation of mTOR
(reviewed in [23]. Thus, as a genetically defined approach to
further examine the role of epithelial mTOR in accelerated wound
healing, we conditionally excised Tsc1 from keratinocytes thereby
activating mTOR by perturbing a negative regulatory step acting
immediately downstream from PI3K and Akt. After wounding, the
area of the wounds was measured daily (Figures 5A and 5B) and
the time to wound closure was determined. Epithelial specific
excision of Tsc1 accelerates wound healing in vivo (figure 5A, B, &
C), which is evident throughout the healing process as early as day
1( p ,0.0001, Figure 5B). Indeed, the median wound closure time
in K14Cre Tsc1
F/F mice is 9 days, as compared to day 11 in
littermate control mice (p=0.0150, Figure 5C). Histological
analysis of the wounds confirmed the upregulation of mTOR
signaling on the K14Cre Tsc1
F/F mice, which displayed an
overexpression of pS6 in the normal, transitional and the
elongated migrating epithelial tongue of the skin epithelium when
compared to the control mice (Figure 6A). Moreover, ablation of
Tsc1 in the skin compartment resulted in the increased re-
epithelization in the K14Cre Tsc1
F/F mice as judged by the length
of the epithelial tongue (p=0.0381, Figure 6B). Quantification of
the wound size confirmed that K14Cre Tsc1
F/F mice displayed
accelerated wound closure (p=0.0048, Figure 6C).
Discussion
There is an urgent need to develop effective approaches to
accelerate the healing of cutaneous wounds. In this regard,
mTOR Accelerates Wound Healing
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10643Figure 2. Accelerated wound closure upon epidermal Pten deletion: Enhanced mTor activation and re-epithelization. (A)
Representative example of accelerated wound closure in Pten-deficient (K14Cre Pten
F/F) mice compared to control mice 4 days after skin wounding.
(B) Quantification of the wound area is represented by the box-and-whiskers graphic (horizontal line, median value; n=13 for each group;
**p=0.0071). (C) Percentage of mice exhibiting open wounds after surgical incision in control mice (triangles, n=8) and K14Cre Pten
F/F mice (squares,
n=8) at the indicated days is depicted. There was a significant increase in the rate of wound closure (***p,0.0001). (D) Representative examples of
K10 and K14 (red-upper panel), pAkt
473 (red-middle panel), and pS6 (red–lower panel) expression in K14Cre Pten
F/F wounds as determined by
immunofluorescence. DAPI (blue) and fibrin(ogen) (green). Note the accumulation of pAkt
473 and pS6 in the transitional zone and epithelial tongue at
the wound edge (transitional and epithelial tongue), when compared to the adjacent epithelium (Normal). (E) Quantification of BrDU positive cells in
histological slides at the transitional and wound edge of control and K14Cre Pten
F/F mice (n=10 for each group; *p=0.0331). (F) Quantification of
epithelial migration and re-epithelization. The length of the epithelial tongue was measured in histological slides of wounded control (n=10) and
K14Cre Pten
F/F mice (n=12) (mean; *p=0.0268).
doi:10.1371/journal.pone.0010643.g002
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do not heal [24], we can now begin to take advantage of the
emerging information on growth promoting pathways in cancer
cells to accelerate the healing of injured tissues. We observed here
that the activation of the PI3K-Akt-mTOR pathway, whose
aberrant function is one of the most frequent events in human
neoplasia, represents an integral component of the normal
cutaneous healing process. Most importantly, we demonstrate
that the targeted activation of this signaling pathway can
dramatically accelerate wound healing rates. Indeed, by the use
of pharmacological and genetically-defined approaches we found
that the activation of the PI3K-Akt pathway enhances the rate of
wound closure dependent on the activation of mTOR, and that
the activation of mTOR in epithelial cells by genetic ablation of
either of two of its upstream regulators, Pten and Tsc1, suffices to
accelerate cutaneous wound healing.
An interesting observation in this study is that the activation of
mTOR innormalepidermis always occursingranular layers, which
represent differentiated non-proliferative cells. This may explain
whymTOR inhibitors do not exert a widespreadcytostatic effect on
normal epithelial cells in vivo, nor do they affect normal skin
function, as suggested by clinical studies and our recently published
reports [15,25,26], together suggesting that the basal keratinocytes
may not strictly depend on mTOR activity to proliferate. However,
during wound healing, mTOR activation is observed in the basal,
subrabasal, and spinous layers of the stratified epithelium adjacent
to the wound wedge and in the migrating epithelial tongue,
suggesting thatboth the proliferativecapacityandmigratoryactivity
of these cells may be controlled by mTOR. In addition, the
formation of the epithelial tongue and wound closure involves of the
interaction between the proliferating and migrating keratinocytes
and the stromal cells. Thus, it is possible that mTOR activity in the
epithelial cells may also regulate the expression of cytokines such as
TGFb,T G F a, FGF, and VEGF, which are known to contribute to
the epithelial/stromal interactions during wound healing (reviewed
in [27,28,29]). In this context, it is possible that mTOR activity in
the epithelial cell compartment may facilitate wound closure by
regulating epithelial cell proliferation and migration, together
with its ability to regulate paracrine mechanisms involved in
cellular communication processes that contribute to the wound
microenvironment.
mTOR inhibitors such as rapamycin (serolimus) have been used
in combination with cyclosporine or tacrolimus in the clinic since
1999 for decreasing the risk of acute allograft rejection episodes, as
it helps preserve the long-term renal function better than high
doses of cyclosporine (CsA) alone [26,30]. The need to activate
mTOR as part of the normal cutaneous healing process may now
explain why mTOR inhibitors can cause a delay in wound closure
as recently reported [21,26]. This potential undesirable side effect
could be controlled with countermeasure therapies or by the
interruption of the treatment with mTOR inhibitors during the
healing process [31].
On the other hand, the PI3K-Akt-mTOR pathway may be
amenable for activation by chemical approaches by the use of small
Figure 3. Keratinocyte migration in vitro is enhanced upon Pten excision. (A) Scratch wound assays in primary cultures of keratinocytes from
control mice and K14Cre Pten
F/F mice. Wounds were generated after cell confluence. In vitro cell migration and wound closure were assessed every
16 h. Areas of migration were measured in duplicates wells using keratinocytes from three distinct mice for each group (dotted line) and represented
in (B) as mean 6 s.e.m. (p=0.0002) (C) Graphics shows cell proliferation represented as the percentage of BrDU incorporation by the primary
keratinocytes. EGF was added where indicated (***p#0.001).
doi:10.1371/journal.pone.0010643.g003
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could be achieved, for example, by the use of PTEN inhibitors,
some of which have been recently described [32,33]. In this regard,
small molecules interfering with PTEN function can enhance
wound closure and rapidly restore lung epithelial monolayer
integrity following injury in relevant models in vitro [34,35].
Although their currentoff-target toxicities may prevent their clinical
application, future studies may provide opportunities for the
development of therapeutically relevant agents inhibiting PTEN
and other molecules on its signaling pathway as a molecular-
targeted approach to accelerate wound healing upon local delivery.
Indeed, based on our current results, we can expect that the
transient and localized activation of mTOR by molecules interfering
with the activity of TSC1 and or TSC2 may represent a direct
approach to trigger mTOR activation with limited interference with
other intracellular signaling routes, thereby reducing unwanted side
effects. In particular, whereas genetic defects in TSC1 and TSC2
may lead to hamartomas, a non-neoplastic proliferative disorder
[36,37], the deletion of Tsc1 did not have a demonstrable impact on
normal biology of the skin, nor did we observe spontaneous tumor
formation in mice with conditional Tsc1 deletion in the skin after
more than one year of observation (not shown). These findings may
provide a rationale for the future development of small molecule
inhibitors of TSC1/TSC2 and/or other molecules suppressing the
mTOR pathway for local delivery to accelerate wound healing.
Whereas the cancer risk of this approach should be carefully
examined, we have recently observed that epithelial stem cells are
endowed with protective mechanisms triggering stem cell differen-
tiation or senescence uponaberrant activation of mTOR [15].Thus,
pharmacological or genetic strategies aimed at the local activation of
mTOR in the epidermis may accelerate the ability to epithelial cells
to migrate and repopulate damaged skin areas hence accelerating
wound closure without resulting in the aberrant growth of basal
keratinocytes and their stem cells.
Overall, our present findings indicate that the transient
pharmacologic activation of the PI3K/Akt/mTOR pathway
may represent a novel clinical intervention strategy to accelerate
the healing of critical sized, debilitating chronic, and life-
threatening wounds in patients.
Materials and Methods
Wound healing assay and experimental mice
This study was approved by the Animal Care and User
Committee (ACUC), according to NIH animal study protocols
approved by the ACUC, protocol 06-408, National Institute of
Figure 4. Rapamycin regulates the Akt-mTOR network in Pten-deficient keratinocytes and delays wound healing. Primary cultures of
keratinocytes isolated from control and K14Cre Pten
F/F mice were treated with vehicle or rapamycin (50 nM), as indicated. Data are representative of
three independent experiments performed in triplicate. (A) Western blot analysis showing very low Pten levels in K14Cre Pten
F/F keratinocytes, which
presented increased levels of both pAkt
Thr308 and pAkt
Ser473. Rapamycin effectively ablates S6 phosphorylation, decreases pAkt
S473, and increases
pAkt
Thr308 in K14Cre Pten
F/F keratinocytes when compared to control keratinocytes. GAPDH provided loading controls. (B) Bar chart represents the
percentage of BrDU positive cells in the primary culture of keratinocytes (***p#0.001). (C and D) The graphic represents the percentage of animals
with open wounds in the control mice (C) and K14Cre Pten
F/F mice group (D) at each indicated day after cutaneous wounding. Rapamycin and vehicle
administration was initiated 48 h before the wounding (see methods for details) and wound closure was used as endpoint; n=8 for each genotype
and time point; p values are indicated.
doi:10.1371/journal.pone.0010643.g004
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‘‘Guide forthe Careand Use ofLaboratoryAnimals’’.Animals were
housed on 12-h light/darkcycles and received food, standard rodent
chow, and water ad libitum in compliance with AAALAC guidelines.
The animals were observed daily by the investigators and animal
care staff. Any animals displaying signs of discomfort, wasting,
ruffled hair coat, hunching, or other signs indicative of distress were
treated appropriately to alleviate discomfort or euthanized if
recommended by animal care staff or the facility veterinary.
Epithelial-specificPtenandTsc1knockoutswereobtainedbycrossing
mice carrying the floxed Pten [38] and Tsc1 alleles [39] with mice
expressing Cre recombinase under the control of cytokeratin 14
promoter (K14-Cre) [40] as previously described [25]. Mice were
anesthetized and dorsal surfaces were shaved and cleaned with 10%
povidone-iodine topical solution. Fifteen millimeters full-thickness
incisional skin wounds were made in the mid-dorsal area. The
wound field was excised and fixed in aqueous buffered zinc formalin
for 24 h, transferred to 70% ethanol, paraffin embedded and
sectioned. The wound sites were monitored and measured daily
utilizing wound closure as endpoint as previously described [41].
Rapamycin administration and Bromodeoxyuridine
(BrDU) incorporation in vivo
Freshly prepared 5-bromo-29-deoxyuridine (BrDU) was injected
intraperitoneally (i.p.) in a concentration of 100 mg/g body weight,
2 h before sacrificing the animals. Rapamycin (LC Laboratories,
MA) was reconstituted in absolute ethanol at 10 mg ml
21 and
stored at 220uC. Rapamycin was diluted in 5.2% Tween-80
(Sigma, MO) and 5.2% polyethyleneglycol (PEG-400, Hampton
Research, CA), and injected intraperitoneally (i.p.) 1 mg/kg every
other day, as reported [25].
Culture of primary keratinocytes, in vitro wound closure
(scratch) assay, BrDU incorporation, and Western blotting
Epidermis of new born mice from control and specific
epidermal knockout mice were used to isolate primary murine
keratinocytes as previous described [42]. Briefly, the mouse skin
was peeled off, stretched out with the dermis faced down in a
60 mm culture dish, and floated on the surface of 0.25% trypsin at
4uC for 18 h. The epidermis was then separated from the dermis,
minced in keratinocyte growth medium (KGM, Gibco, Carlsbad,
CA) supplemented with high Ca
2+. The undigested cornified
fragments were removed by filtering the cell suspension through a
sterile nylon cell strainer. The cells were collected by centrifuga-
tion, resuspended in fresh KGM Ca
2+ supplemented with 10%
FBS, and plated. After 24 h, attached keratinocytes were rinsed
with PBS and incubated with fresh KGM in low Ca
2+. Primary
keratinocytes were assay with BrDU incorporation. After 24 hours
starvation, cells were left untreated or treated for 24 h with 10 ng/
ml EGF and 50 nM Rapamycin where indicated; and 10 mM
Figure 5. Accelerated wound closure in upon epithelial Tsc1 excision. Representative photographs of control and K14Cre Tsc1
F/F mice at the
indicated days after wounding. (B) Quantification of the wound area. Results represent the mean 6 s.e.m; n=8 for each time point and genotype.
(***p,0.0001) (C) Graphic representation of the percentage of animals displaying open wounds in control mice (A) and K14Cre Tsc1
F/F mice (B) at
each depicted time (days) (*p=0.0150).
doi:10.1371/journal.pone.0010643.g005
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fixative and then treated with 2 N HCl. BrDU was detected by
immunofluorescence with anti-BrDU antibody (Axyll-Accurate
Chemical & Scientific Corporation, Westbury, NY). Images were
taken using Zeiss Axio Imager Z1 microscope equipped with an
Apotome device (Carl Zeiss, Thornwood, NY). Quantitative
analyses were performed by counting the total number of cells
and cells expressing nuclear BrDU stain. Scratch assays were
Figure 6. Acceleration of wound healing upon ablation of Tsc1 in the skin. (A) Representative examples of immunofluorescence in
histological sections of incisional skin wounds in mice; pS6 (red), fibrin(ogen) (green), DAPI (blue), as above. The white dotted line delineates the
epithelial layer from the underlining dermis. Note the expansion of pS6 (red) expression in the normal, transitional and elongated migrating tongue
of the epithelial compartment of the K14Cre Tsc1
F/F mice when compared to control mice. Scale bar, 50 mm. (B) Representative H&E stained sections
showing enhanced re-epithelization of the wound area as reflected by the length of the migrating epithelial tongue in the K14Cre Tsc1
F/F mice when
compared to the control mice. The black lines delineate the epithelial migrating tongue. Quantification of the epithelial tongue from each genotype
is represented by the dot plot (n=10 for each genotype; scale bar, 200 mm; *p=0.0381). (C) Representative histological sections of wounded skin
from control and K14Cre Tsc1
F/F mice. The black line indicates the wound width, and the scatter plot represents the quantification of the wound
width from control and K14Cre Tsc1
F/F mice (n=6 mice per genotype; scale bar, 400 mm; **p=0.0048).
doi:10.1371/journal.pone.0010643.g006
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coated wells and starved overnight. Scratches were made with a
plastic pipette tip across the diameter of each well. Quantitative
analysis of the scratch area of closure was performed using the
Axiovision Rel. 4.7 (Carl Zeiss, Thornwood, NY). Cells were also
lysed and 30 mg of cellular proteins were separated on 10% SDS-
PAGE, transferred to nitrocellulose membranes, and analyzed by
Western blot using primary antibodies against Akt, phospho-
specific Akt (pAkt
Ser473 and pAkt
Thr308) and S6 (pS6) (Cell
Signaling Technology, MA), PTEN (Cascade Bioscience, MA),
and GAPDH (Santa Cruz Biotechnology, CA). Results are
representative of three independent experiments performed in
triplicate.
Histology and Immunofluorescence
Haematoxylin-Eosin (H&E) staining was performed on formalin-
fixed and paraffin-embedded 4 mm serial sections according to
standard procedures. Immunofluorescence was performed on cells
and tissue sections after antigen-retrieval using antibodies developed
against Cytokeratin 10 (K10) and Cytokeratin 14 (K14) (Covance,
Princeton, NJ), Fibrin(ogen) (Dako, CA); pAkt
Ser473 and pS6 (Cell
Signaling Technology, MA), and BrDU (Axyll-Accurate Chemical
& Scientific Corporation, Westbury, NY), and rhodamine-X or
FITC-conjugated secondary antibodies (Jackson Immunoresearch
Laboratories, West Grove, PA) as described previously[15]. For
nuclear staining, propidium iodide or mounting media with DAPI
(Vector Laboratories, Burlingame, CA) was used. Images were taken
using Zeiss Axio Imager Z1 microscope equipped with an Apotome
device (Carl Zeiss, Thornwood, NY) and ScanScope (Aperio, CA).
Quantitative analysis of the migrating epithelial tongue and wound
size were done with ImageScope (Aperio, CA) and Axiovision Rel.
4.6 (Carl Zeiss, Thornwood, NY). H&E stain and immunofluores-
cence were performed in all the samples from every control and
transgenic mice.
Statistical analysis
Statistical analyses were performed by ANOVA analysis of
variance test, followed by the Bonferroni’s multiple comparison.
The Kaplan-Meier analysis followed by log rank test was
performed to analyze time to wound closure. T-test was used for
comparisons of histological wounded size and area, migration of
the epithelial tongue, and BrDU incorporation using GraphPad
Prism 4.03 (GraphPad Software, San Diego, CA). Asterisks denote
statistic significance (NS, P.0.05; * P,0.05; ** P,0.01; and ***
P,0.001).
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